BCMA/CD3 bispecific antibody
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for BCMA/CD3 bispecific antibody, covering 2026-02-12 to 2026-03-24. Get the full timeline:
Most recent: Clinical Trial Update: BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis [Phase 2]